PDF herunterladen
Open Access
CC BY 4.0 · Indian J Med Paediatr Oncol 2024; 45(02): 176-182
DOI: 10.1055/s-0044-1779721
Brief Communication

Pharmacoeconomic Analysis of Treating Lung Cancer with Different Regimens Using the Cheapest and Costliest Brand and the Generic Jan Aushadhi Drugs Marketed in India

Autor*innen

  • Abhishek Krishna

    1   Department of Radiation Oncology, Mysore Medical College and Research Institute, Mysuru, Karnataka, India

  • Princy Louis Palatty 

    2   Department of Pharmacology, Amrita Institute of Medical Sciences, Amrita Vishwa Vidyapeetham, Ernakulam, Kerala, India

  • Thomas George

    3   Department of Internal Medicine, Coney Island Hospital, Brooklyn, New York, United States

  • Manjeshwar Shrinath Baliga 

    4   Research Unit, Mangalore Institute of Oncology, Pumpwell, Mangaluru, Karnataka, India

Source of Funding None declared.
Weitere Informationen
Auch verfügbar auf
  Lizenzen und Reprints

Abstract

Background/Purpose of the Study The costs of chemotherapy drugs which are vital in the treatment of lung cancer can be exorbitant. The current study was undertaken to ascertain cost minimization analysis by comparing costliest and cheapest branded with Jan Aushadhi (JA) drugs marketed in India.

Methods The cost of costliest, cheapest branded, and JA drugs were collected from the designated reference sites. The cost difference, cost ratio, and percentage of cost variation were calculated as per cost minimization study guidelines.

Results The results of the analysis suggest that the JA drugs were much cheaper than the branded drugs and when used in regimens resulted in substantial cost savings. The biggest financial advantage was seen in the commonly used cisplatin–pemetrexed regimen where cost saving of Rs. 268,002 was observed for the whole treatment of six cycles. Using JA drugs also reduced the cost for the targeted therapy with gefitinib and erlotinib.

Conclusion The cost minimization study, which is the first in this field of lung cancer, clearly indicates the usefulness of JA drugs in reducing financial costs for the patient.

Keywords

lung cancer - anticancer drugs - pharmacoeconomics - Jan Aushadhi - cost difference - cost ratio - percentage of cost variation

Ethics

No patient-specific data or information were required for the study focus on the pharmacoeconomics of drug pricing. Cost of data on medications is available in public domain, and the study did not require approval from an Institutional Review Board.


Ethics Committee Approval

Not required.




Publikationsverlauf

Artikel online veröffentlicht:
21. März 2024

© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India